AI assistant
Sending…
CRISPR Therapeutics AG — Director's Dealing 2020
Jun 25, 2020
30936_dirs_2020-06-25_f4644d32-a0d4-4e0f-94a0-62f58e888148.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2020-06-23
Reporting Person: Novak Rodger (Director, President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-06-23 | Common Shares | S | 50000 | $75.00 | Disposed | 698007 | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
More from CRISPR Therapeutics AG
Regulatory Filings
2026
Jun 5
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 4
Regulatory Filings
2026
May 4
Annual Report
2026
Apr 21
Proxy Solicitation & Information Statement
2026
Apr 21
Director's Dealing
2026
Mar 24
Director's Dealing
2026
Mar 24
Director's Dealing
2026
Mar 24
Director's Dealing
2026
Mar 24
Director's Dealing
2026
Mar 17